CSV May 8, 2022 through May 8, 2024 See all Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
METARAMINO	ADDITIONAL R	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In USP

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
L BITARTRATE	EQUIREMENTS/*USP Reference Standards ?11?*							Metaraminol Enantiomer RS: Change 3-[(1*S*,2*R*)-2-Amino-1-hydroxypropyl]phenol. $C_9H_{13}NO_2$ 167.21 to: 3-[(1*S*,2*R*)-2-Amino-1-hydroxypropyl]phenol D-tartrate. $C_9H_{13}NO_2$? $C_4H_6O_6$ 317.29
METAPROTERENOL SULFATE TABLETS	*Identification/A.*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Change Proceed as directed in *Identification* test *A* under *Metaproterenol Sulfate Inhalation Solution*, beginning with “Allow the spots to dry”: to: Allow the spots to dry, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								develop the chromatogram in a solvent system consisting of the upper layer of a freshly prepared mixture of butyl alcohol, water, and formic acid (50:25:7) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, and allow the solvent to evaporate. Locate the spots on the plate by examination under short-wavelength UV light:

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
METAPROTERENOL SULFATE ORAL SOLUTION	*Identification/A.*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Change Proceed as directed in *Identification* test *A* under *Metaproterenol Sulfate Inhalation Solution*, beginning with “Allow the spots to dry”: to: Allow the spots to dry, and develop the chromatogram in a solvent system consisting of the upper layer of a freshly prepared mixture of butyl alcohol, water, and formic acid (50:25:7) until the solvent front has moved about three-fourths of the length of the

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								plate. Remove the plate from the developing chamber, mark the solvent front, and allow the solvent to evaporate. Locate the spots on the plate by examination under short-wavelength UV light:
MESO-ZEAXANTHIN PREPARATION	IDENTIFICATION/*C*.	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin
MESO-ZEAXANTHIN PREPARATION	COMPOSITION/*Stereoisomeric Composition*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *System suitability*: Change [Note—The approximate relative retention times for (3*S*,3?*S*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-zeaxanthin, (3*R*,3?*S*-*meso*)-zeaxanthin, (3*R*,3?*R*)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are 0.94, 1.00, 1.06, and 1.11, respectively.] to: [Note—The approximate relative retention times for (3*S*,3?*S*)-zeaxanthin, (3*R*,3?*S*)-zeaxanthin, (3*R*,3?*R*)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are 0.94, 1.00, 1.06, and 1.11, respectively.] AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								
								In *System suitability/Suitability requirements/Resolution*: Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Analysis*: Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Acceptance criteria*: Change (3*R*,3?*S*-*meso*)-Zeaxanthin to: (3*R*,3?*S*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MESO-ZEAXANTHIN PREPARATION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	)-Zeaxanthin In USP *meso* -Zeaxanthin RS: Change (3*R*,3?*S*-*meso*)-Zeaxanthin. to: (3*R*,3?*S*)-Zeaxanthin.
MESO-ZEAXANTHIN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	In USP *meso* -Zeaxanthin RS: Change (3*R*,3?*S*-*meso*)-Zeaxanthin. to: (3*R*,3?*S*)-Zeaxanthin.
MESO-ZEAXANTHIN	CHEMICAL INFORMATION	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	Change (3*R*,3?*S*-*meso*)-Zeaxanthin to: (3*R*,3?*S*)-Zeaxanthin
MESO-ZEAXANTHIN	IDENTIFICATION/*C*.	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	Change (3*R*,3?*S*-*meso*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin
MESO-ZEAXANTHIN	COMPOSITION /*Stereoisomeric Composition*	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	In *System suitability*: Change [Note—The approximate relative retention times for (3*S*,3?*S*)-zeaxanthin, (3*R*,3?*S*-*meso*)-zeaxanthin, (3*R*,3?*R*)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are 0.94, 1.00, 1.06, and 1.11, respectively.] to: [Note—The approximate relative retention times for

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(3*S*,3?*S*)-zeaxanthin, (3*R*,3?*S*)-zeaxanthin, (3*R*,3?*R*)-zeaxanthin, and (3*R*,3?*R*,6?*R*)-lutein are 0.94, 1.00, 1.06, and 1.11, respectively.] AND In *System suitability/Suitability requirements/Resolution*: Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Analysis*: Change (3*R*,3?*S*-

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								meso)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin AND In *Acceptance criteria*: Change (3*R*,3?*S*-*meso*)-Zeaxanthin to: (3*R*,3?*S*)-Zeaxanthin
MELOXICAM ORAL SUSPENSION	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	29-Jul-2022	1-Aug-2022	*NA*	*NA*	In *Analysis*: Change W_U = weight of the Oral Suspension taken (mg) to: W_U = weight of the Oral Suspension taken (g)
MELENGESTROL ACETATE	CHEMICAL INFORMATION	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	Change 396.52 to: 396.53
MELENGESTROL ACETATE	*USP Reference standards ?11?*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In USP Melengestrol

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Acetate Related Compound A RS: Change 16-Methylene-17?-hydroxy-4-pregnene-3,20-dione 17-acetate. to: 16-Methylene-3,20-dioxopregn-4-en-17-yl acetate. AND In USP Melengestrol Acetate Related Compound B RS: Change 17?-Hydroxy-6,16-dimethylene progna-4-ene-3,20-dione 17-acetate. to: 6,16-Dimethylene-3,20-dioxopregn-4-en-17-yl acetate.
MAGNESIUM OXIDE	IM PURITIES/*Limit of Calcium*	*USPNF Online*	Online	25-Feb-2022	1-Dec-2022	*NA*	*NA*	In *Analysis*: Change *C*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U$= concentration of Magnesium Hydroxide in the *Sample solution* (mg/mL) to: C_U = concentration of Magnesium Oxide in the *Sample solution* (mg/mL)
MAFENIDE ACETATE FOR TOPICAL SOLUTION	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *System suitability*: Change **Samples**: *System suitability solution*, *Standard solution A*, and *Standard solution B* to: **Samples**: *System suitability solution* and *Standard solution A*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								AND In *Analysis*: Change **Samples**: *Mobile phase*, *Standard solution A*, and *Sample solution* Chromatograph the *Standard solution* and adjust the integration parameters so that the response is 5%–15% of full-scale deflection. to: **Samples**: *Mobile phase*, *Standard solution A*, *Standard solution B*, and *Sample solution* Chromatograph *Standard solution B* and adjust the

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								integration parameters so that the response is 5%–15% of full-scale deflection.
LYSINE HYDROCHLORIDE	IM PURITIES/*Related Compounds*	*USPNF Online*	Online	16-Dec-2022	1-Jun-2023	*NA*	*NA*	In *Chromatographic system*/*Spray reagent*: Change 0.2 g of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5) to: 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5)
LYSINE ACETATE	IM PURITIES/*Related Compounds*	*USPNF Online*	Online	16-Dec-2022	1-Jun-2023	*NA*	*NA*	In *Chromatographic system*/*Spray reagent*: Change 0.2 g of ninhydrin in a

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mixture of butyl alcohol and 2 N acetic acid (95:5) to: 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5)
LINEZOLID TABLETS	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	In *Sensitivity solution*: Change 0.5 ug/mL of USP Linezolid RS from *Standard solution* in *Diluent* to: 0.5 ?g/mL of USP Linezolid RS from *Standard solution* in *Diluent*
LINEZOLID TABLETS	PERFORMANC E TESTS	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	In *Dissolution* ?711?/*Test 1*/*Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times 100$ r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) V = volume of *Medium*, 900 mL L = label claim (mg/Tablet) to: Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times D \times 100$ r_U = peak response of

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) *V* = volume of *Medium*, 900 mL *L* = label claim (mg/Tablet) *D* = dilution factor of the *Sample solution*, as needed
LIDOCAINE, RACEPINEPHRINE AND TETRACAINE HYDROCHLORIDES COMPOU	DEFINITION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	Change Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NDED TOPICAL GEL								Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Sterile Preparations* <797>). to: Prepare Lidocaine, Race pinephrine, and Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Nonsterile Preparations* <795>).
LIDOCAINE HYDROCHLORIDE AND DEXTROSE INJECTION	*Assay for lidocaine hydrochloride*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Change Proceed with Injection as directed in the *Assay for lidocaine hydrochloride* under *Lidocaine and Epinephrine Injection*. to: Proceed with Injection as directed in the *Assay for lidocaine hydrochloride* under *Lidocaine*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Hydrochloride and Epinephrine Injection.
LIDOCAINE	ASSAY	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Procedure*: Change **Column:** 3.9-mm × 30-cm; 4-µm packing L1 to: **Column:** 3.9-mm × 30-cm; 10-µm packing L1
LEVORPHANOL TARTRATE TABLETS	PERFORMANCE TESTS/ *Uniformity of Dosage Units* ?905?	*USPNF Online*	Online	31-Mar-2023	1-Aug-2023	*NA*	*NA*	In *Sample solution*: Change Nominally about 80 ug/mL of levorphanol tartrate in *Diluent* prepared as follows. to: Nominally about 80 µg/mL of levorphanol tartrate in

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LATANOPROST	ASSAY/ *Procedure*	*USPNF Online*	Online	29-Jul-2022	1-Dec-2022	*NA*	*NA*	*Diluent* prepared as follows. Change **Standard solution**: Transfer 2.0 mg/mL of USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume. **Sample solution**: Transfer 2.0 mg/mL of Latanoprost into a suitable volumetric flask, dissolve in dehydrated

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume. to: **Standard solution**: 2.0 mg/mL of USP Latanoprost RS prepared as follows. Transfer USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume. **Sample solution**

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								: 2.0 mg/mL of Latanoprost prepared as follows. Transfer Latanoprost into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume.
LANSOPRAZOLE DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	30-Sep-2022	1-Oct-2022	*NA*	*NA*	Delete **Blank**: Methanol and *Diluent* (1:9)
IVERMECTIN	CHEMICAL INFORMATION	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	Change $C_{48}H_{74}O_{14}$ (Component H_2B_{1a}) 875.09 $C_{47}H_{72}O_{14}$ (Component H_2B_{1b}) 861.07 Component

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								H_2B_{1a}: Avermectin A_{1a}, 5-*O*-demethyl-22,23-dihydro-. (2a*E*,4*E*,8*E*)-(5?*S*,6*S*,6?*R*,7*S*,11*R*,13*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-6?-(*S*)-*sec*-Butyl-3?,4?,5?,6,6?,7,10,11,14,15,17a,20,20a,20b-tetradecahydro-20,20b-dihydroxy[11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2?-[2*H*]pyran]-7-yl 2,6-dideoxy-4-*O*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								*O* -me thyl-?- L- *arabino* -hexopyranosyl) -3-*O*-methyl-?- L- *arabino* -hexopyranosid e CAS RN®: 70161-11-4. Component H_2B_{1b}: Avermectin A_{1a}, 5-*O* -demethyl-25-d e(1-methylprop y l)-22,23-dihydro -25-(1-methylet hyl)-. (2a*E*,4*E*,8*E*)-(5?*S*,6*S*,6?*R* ,7*S*,11*R*,13*R* ,15*S*,17a*R* ,20*R*,20a*R* ,20b*S*)-3?,4?,5?,6,6?, 7,10,11,-oxospir o[11,15-methan

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								o-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2?[2*H*]pyran]-7-yl 2,6-di deoxy-4-*O*
								O-methyl-?-L-*arabino*-hexopyranosyl)-3-*O*-methyl-?-L-*arabino*-hexopyranoside CAS RN®: 70209-81-3; UNII: 0W28CYI3TU. to: $C_{48}H_{74}O_{14}$ (Component H

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								$_2B_{1a}$) 875.11 $C_{47}H_{72}O_{14}$ (Component H_2B_{1b}) 861.08 Component H_2B_{1a}: Avermectin A_{1a}, 5-*O* -demethyl-22,23 -dihydro-. (2a*E*,4*E*,8*E*)-(5'*S*,6*S*,6'*R* ,7*S*,11*R*,13*R* ,15*S*,17a*R* ,20*R*,20a*R* ,20b*S*)-6'-(*S*)- *sec* -Butyl-3',4',5', 6,6',7,10,11,14, 15,17a,20,20a,2 0b-tetradecahyd ro-20,20b-dihyd roxy-5',6,8,19-t etramethyl-17-o xospiro [11,15- meth ano-2*H*,13*H* ,17*H* -furo[4,3,2-*pq*][2,6]benzodiox

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								
								acyclooctadecin-13,2’-[2*H*]pyran]-7-yl 2,6-dideoxy-4-*O*
								O-methyl-?-L-*arabino*-hexopyranosyl)-3-*O*-methyl-?-L-*arabino*-hexopyranoside CAS RN®: 71827-03-7; UNII: 91Y2202OUW. Component H_2B_{1b}: Avermectin A_{1a}, 5-*O*-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylet

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								hyl)-. (2a*E*,4*E*,8*E*)-(5’*S*,6*S*,6’*R*,7*S*,11*R*,13*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-3’,4’,5’,6,6’,7,10,11,14,15,17a,20,20a,20b-Tetradecahydro-20,20b-dihydroxy-6’-isopropyl-5’,6,8,19-tetramethyl-17-oxospiro [11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2’-[2*H*]pyran]-7-yl 2,6-dideoxy-4-*O* *O*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-me thyl-?- L- *arabino* -hexopyranosyl) -3-*O*-methyl-?- L- *arabino* -hexopyranosid e CAS RN®: 70209-81-3; UNII: 0W28CYI3TU.
ISOSORBIDE MONONITRATE TABLETS	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impuri ties*/*Standard solution*: Change isosorbide related compound A to: isosorbide mon onitrate related compound A AND In *System suitabil ity*/*Suitability re quire*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								*ments*/*Relative standard deviation*: Change isosorbide related compound A, to: isosorbide mon onitrate related compound A, AND In four instances in *Analysis*: Change isosorbide related compound A, to: isosorbide mon onitrate related compound A, AND In *Table 1*: Change Isosorbide related compound A to: Isosorbide mon

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								onitrate related compound A
ISOFLURANE	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Analysis*: Change Result = $(r_U/r_S) \times C_S \times (1/F)$ to: Result = $(r_U/r_S) \times C_F \times (1/F)$ AND Change C_S = final concentration of USP Isoflurane Related Compound B RS in the *Standard solution* (%) to: C_F = final concentration of USP Isoflurane Related Compound B RS in the *Standard solution* (%)
ISOBUTYL ALCOHOL	ASSAY/ *Procedure*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change *r*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								s= sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the *Reference solution* to: r_T = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the *Reference solution*
IRINOTECAN HYDROCHLORIDE INJECTION	DEFINITION	*USPNF Online* Online		26-Aug-2022	1-Sep-2022	*NA*	*NA*	Change NTL 90.0% and NMT 110.0% to: NLT 90.0% and NMT 110.0%
IPRATROPIUM BROMIDE	IMPURITIES	*USPNF Online* Online		29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Organic Impurities*:

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INHALATION SOLUTION								Change **Column:** 4.6-mm × 25-µm; 5-µm packing L1 to: **Column:** 4.6-mm × 25-cm; 5-µm packing L1
IODIXANOL INJECTION	IMPURITIES	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Organic Impurities, Procedure 2*/footnote 4: Change 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl](acetylimino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]-2-hy droxypropyl]oxy]-2-hydrox

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ypropyl](acetylimino)]-*N*,*N*'-bis(2,3-dihy droxypropyl)-2,4,6-triiodo-1,3-benzendicarboxamide. to: 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl](acetylamino)]-2-hydroxypropyl](acetylamino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]-2-hydroxypropyl]oxy]-2-hydroxypropyl](acetylamino)]-*N*,*N*'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzendicarboxamide.
IODIXANOL	ADDITIONAL R	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *USP*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION	EQUIREMENTS							*Reference Standards* ?11?/USP Iodixanol Related Compound E RS: Change 5-[[3-[[3-[[(2,3-Dihydroxypropyl)amino]carbonyl]-5- [[amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl]-(acetylimino)]-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide. to: 5-{*N*-[3-(*N*-{3-Carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-N^1,N^3-bis(2,3-dihydro

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								xypropyl)-2,4,6-triiodoisophthalamide.
IBUPROFEN ORAL SUSPENSION	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Analysis*: Change Result = (R_U/R_S) x C_S x V x (D/W_U) x $(1/L)$ x 100 R_U = peak area ratio of ibuprofen to benzophenone from the *Sample solution* R_S = peak area ratio of ibuprofen to benzophenone from the *Standard solution* C_S = concentration of USP Ibuprofen RS in the *Standard solution* (mg/mL) V = volume of *Medium*, 900

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sort ascending								mL *D* = density of Oral Suspension (g/mL) W_U = weight of the portion of Oral Suspension added to the *Medium* (g) *L* = label claim (mg/mL) to: Result = $(R_U/R_S) \times C_S \times V \times (d/W_U) \times D \times (1/L) \times 100$ R_U = peak area ratio of ibuprofen to benzophenone from the *Sample solution* R_S = peak area ratio of ibuprofen to benzophenone from the *Standard solution*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_S = concentration of USP Ibuprofen RS in the *Standard solution* (mg/mL) V = volume of *Medium*, 900 mL d = density of Oral Suspension (g/mL) W_U = weight of the portion of Oral Suspension added to the *Medium* (g) D = dilution factor of the *Sample solution*, 2 L = label claim (mg/mL)
HYDROCODONE BITARTRATE AND HOMATROPINE METHY	ASSAY/ *Procedure*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In *Buffer*: Change Adjust with phosphoric acid to a pH of 6.4 ±

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LBROMIDE TABLETS								0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1.
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS	IMPURITIES/*Limit of Homatropine Hydrobromide and Related Substances*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In *Buffer*: Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1.
HOMATROPINE HYDROBROMIDE	CHEMICAL INFORMATION	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	Change 356.25 to: 356.26 AND Change 1?H,5?H-Tropan-3?-ol mandelate (ester) hydrobromide to: (1*R*,3*r*,5*S*)-8-Methyl-8-az

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								abicyclo[3.2.1]octan-3-yl 2-hydroxy-2-phenylacetate hydrobromide
GLYCYL-L-TYROSINE	IM PURITIES/*Related Compounds*	*USPNF Online*	Online	24-Feb-2023	1-Jun-2023	*NA*	*NA*	In *Buffer solution*: Change Dissolve 6.84 g of potassium phosphate in 1000 mL of water. to: Dissolve 6.84 g of monobasic potassium phosphate in 1000 mL of water.
GLUCAGON	PROCESS-RELATED IMPURITIES AND OTHER COMPONENTS	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In *Acetic Acid in Peptides/Analysis*: Change C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (mg/mL)

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (µg/mL) AND In *Ammonium/Analysis*: Change C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (mg/mL) to: C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (µg/mL)
FOSAMPRENAVIR CALCIUM	PERFORMANCE TESTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Dissolution* ?711?/*Medium*:

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS								Change 26.7 g/L of sodium acetate trihydrate in water. Add 133 mL of glacial acetic acid to this solution, and then dilute with water to 10 L; 900 mL. to: 0.02 M sodium acetate buffer, pH 3.5, prepared as follows. Dissolve 2.67 g of sodium acetate in 100 mL of water. Add 13.3 mL of glacial acetic acid and then dilute with water to 1000 mL; 900 mL.
FORSKOHLII	COMPOSITION /*Content of Forskolin*	*USPNF Online*	Online	29-Jul-2022	1-Aug-2022	*NA*	*NA*	In *Chromatographic system*: Change

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Column: 4.6-mm × 25-cm; 5-µm, 100 Å to: Column: 4.6-mm × 25-cm; 5-µm, 100 Å; packing L1
FLUVOXAMINE MALEATE TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Solution A*: Change 8 g/L of 1-pentanesulfonic acid sodium salt and 1 g/L of monobasic potassium phosphate in water. to: 8 g/L of 1-pentanesulfonic acid sodium salt and 1.1 g/L of monobasic potassium phosphate in water.
FLUTICASONE PROPIONATE	IM PUR	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NASAL SPRAY	ITIES/*Organic Impurities*							Samples: *System suitability solution*, *Identification solution*, and *Sample solution* to: Samples: *Identification solution* and *Sample solution*
FLUTICASONE PROPIONATE NASAL SPRAY	OTHER COMPONENTS/*Content of Phenylethyl Alcohol*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Sample solution*: Change Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask. Add about 40 mL of *Diluent*, and sonicate for 10 min until the supernatant is clear. Use the clear supernatant for analysis. to: Transfer 1.0 g

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of the Nasal Spray to a 50-mL volumetric flask. Add about 40 mL of *Diluent*, and sonicate for 10 min. Dilute with *Diluent* to volume, and shake. Allow to stand for 10 min until the supernatant is clear. Use the clear supernatant for analysis.
FLURAZEPAM HYDROCHLORIDE	USP REFERENCE STANDARDS ?11?	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In USP Flurazepam Related Compound C RS: Change 5-Chloro-2-(2-diethylaminoethyl(amino)-2?-fluorobenzophenone hydrochloride. to: 5-Chloro-2-(2-diethylaminoethyl

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								amino)-2?-fluorobenzophenone hydrochloride.
FLUOCINOLONE ACETONIDE	*Organic Impurities*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Acceptance criteria/Total impurities*: Change NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone acetonide from the *Standard solution*. to: NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone acetonide from the *Sample solution*.
FELODIPINE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	Change **Buffer**, **Mobile phase**, **System suitability solution**,

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution, **Sample solution**, and **Chromatographic system**: Proceed as directed in the *Assay*. to: **Buffer**, **Mobile phase**, **System suitability solution**, **Standard solution**, **Sample solution**, and **Chromatographic system**: Proceed as directed in the *Assay*, and use 40 µL injection volume for the *Sensitivity solution*.
ESCITALOPRAM TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Buffer*: Change Adjust with 1 N

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sodium hydroxide VS to a pH of 5.2. to: Adjust with 1 N sodium hydroxide to a pH of 5.2.
ESCITALOPRAM TABLETS	PERFORMANCE TESTS/ *Dissolution ?711?*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Test 1*/*Medium*: Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL AND In *Test 2*/*Medium*: Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ERYTHROMYCIN ETHYLSUCCINATE FOR ORAL SUSPENSION	*Identification*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Change Proceed as directed in the *Identification* test under *Erythromycin Ethylsuccinate Oral Suspension*, beginning with “Prepare a Standard solution.” to: Prepare a Standard solution of USP Erythromycin Ethylsuccinate RS in methanol containing about 3 mg per mL. Apply separately 10 µL each of the test solution and the Standard solution to a suitable thin-layer chromatog

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								raphic plate (see *Chromatography* ?621?) coated with a 0.25-mm layer of chromatographic silica gel mixture, and allow to dry. Place the plate in an unlined chromatographic chamber, and develop the chromatograms in a solvent system consisting of a mixture of methanol and chloroform (85:15) until the solvent front has moved about 9 cm. Remove the plate from the chamber, mark the solvent front, and allow the solvent to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								evaporate. Spray the plate with a mixture of dehydrated alcohol, *p* -methoxybenzal dehyde, and sulfuric acid (90:5:5). Heat the plate at 100° for 10 minutes, and examine the chromatograms, in which the erythromycin and succinic acid moieties appear as black-to-purple spots: the R_F values of the principal spots obtained from the test solution correspond to those obtained from the Standard solution.

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Current page 3
- Page 4
- Page 5
- Page 6
- Next page Next ›
- Last page Last »